Open AccessPhase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1
Author(s) -
Brinda Emu,
Jeffrey Fessel,
Shan Schrader,
Princy Kumar,
Gary Richmond,
Sandra Win,
Steven P. Weinheimer,
Christian Marsolais,
Stanley T. Lewis
Publication year - 2018
Publication title -
new england journal of medicine
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 19.889
H-Index - 1030
eISSN - 1533-4406
pISSN - 0028-4793
DOI - 10.1056/nejmoa1711460
Subject(s) - liter , viral load , medicine , regimen , population , immunology , human immunodeficiency virus (hiv) , virology , environmental health
Ibalizumab, a humanized IgG4 monoclonal antibody, blocks the entry of human immunodeficiency virus type 1 (HIV-1) by noncompetitive binding to CD4.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom